publication date: Dec. 22, 2016

NCI CTEP-Approved Trials for December

NCI CTEP approved the following clinical research studies last month. For further information, contact the principal investigator listed.

Phase I          NRG-HN003

A Phase I and Expansion Cohort Study of Adjuvant Cisplatin, Intensity-Modulated Radiotherapy, and MK-3475 (Pembrolizumab) in High-Risk Head and Neck Squamous Cell Carncinoma (HNSCC)

NRG Oncology

Bauman, Julie E.

(520) 626-5972


Phase I/II       9948

Phase 1 Dose Escalation and Randomized Phase 2 Trial of Carboplatin and Gemcitabine with or without VX-970 in First Recurrence Platinum-Sensitive Epithelial Ovarian, Peritoneal, and Fallopian Tube Cancer

Mayo Clinic Cancer Center LAO

Wahner Hendrickson, Andrea E.

(507) 266-9161


Phase II         10020

A Phase II Multiple-Arm, Open-Label, Randomized Study of PARP Inhibition (Veliparib; ABT-888) and Anti-PD-L1 Therapy (Atezolizumab; MPDL3280A) Either Alone or in Combination in Homologous DNA Repair (HDR) Deficient Triple Negative Breast Cancer (TNBC)

Yale University Cancer Center LAO

LoRusso, Patricia Mucci

(203) 785-5944


Phase II         9767

An Open Label, Multicenter, Single Arm Phase II Study to Evaluate the Activity and Tolerability of the Novel mTOR Inhibitor, MLN0128 (TAK-228), in Patients with Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelial Tract Whose Tumors Harbor a TSC1 and/or … Continue reading CCL Dec 2016 – NCI CTEP-Approved Trials for December

To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2017 The Cancer Letter Inc.